SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Invitae Corporation
(NYSE: NVTA), a leading medical genetics company, has joined eMERGE
Network, a nationwide effort organized and funded by the National
Human Genome Research Institute (NHGRI) that connects genetic data
and electronic medical record (EMR) systems to advance the use of
genetics in healthcare. As a new clinical affiliate, Invitae will
provide genetic testing for a study of up to 25,000 patients to
evaluate the impact of population screening.
![Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation) Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)](https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg)
"Our own research has shown that people can harbor a genetic
change that could put them at increased risk for conditions like
cancer and heart disease. The eMERGE study is part of the work
conducted by the NHGRI to improve understanding of these rates in
diverse populations, with an emphasis on underrepresented
minorities, and identify best practices for population screening,"
said Robert Nussbaum, M.D., chief
medical officer at Invitae. "We're proud to be participating in
this important effort, through which we hope to not only help
provide information that study participants can use to improve
their health but also contribute important findings that may
improve healthcare for all."
Participants enrolled in the study conducted through the effort
will receive genetic testing through Invitae to identify genetic
changes linked to conditions such as coronary artery disease,
hereditary breast and ovarian cancer, and Lynch syndrome, along
with access to follow-up testing for family members. In addition to
testing, Invitae will provide clinical resources for participants
in the study, including the opportunity to interact with Gia,
Invitae's advanced clinical chatbot, to learn more about the
genetic testing process and what their results mean.
Using findings about genetic changes and information from EMRs,
study researchers will work to deepen understanding of the
connections between genetics and health and to develop ways to put
that knowledge into practice to help improve patient care.
Importantly, participating study sites are particularly focused on
including diverse populations, such as underrepresented minority
populations, underserved populations, or populations who experience
poorer medical outcomes.
About eMERGE Network
eMERGE is a national network
organized and funded by the NHGRI, of the NIH, that combines DNA
biorepositories with electronic medical record (EMR) systems to
establish protocols and methodologies for improved genomic risk
assessments for diverse populations and to integrate their use in
clinical care. NHGRI first initiated the eMERGE Network in 2007 and
began the fourth phase in July 2020.
The Network brings together researchers with a wide range of
expertise in genomics, statistics, ethics, informatics, and
clinical medicine from leading medical research institutions across
the country to conduct research in genomics, including discovery,
clinical implementation and public resources. In addition, the
consortium includes a focus on social and ethical issues such as
privacy, confidentiality, and interactions with the broader
community. More information is available at the eMERGE website.
About Invitae
Invitae Corporation (NYSE: NVTA) is
a leading medical genetics company, whose mission is to bring
comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time, and lower prices. For more
information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the design and objectives of the study; and the
company's expectations regarding the outcomes of the study.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: the company's history of losses; the company's
ability to compete; the company's failure to manage growth
effectively; the company's need to scale its infrastructure in
advance of demand for its tests and to increase demand for its
tests; the company's ability to use rapidly changing genetic data
to interpret test results accurately and consistently; security
breaches, loss of data and other disruptions; laws and regulations
applicable to the company's business; and the other risks set forth
in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's Annual
Report on Form 10-K for the year ended December 31, 2020. These forward-looking
statements speak only as of the date hereof, and Invitae
Corporation disclaims any obligation to update these
forward-looking statements.
Source: Invitae Corporation
Contact:
Laura D'Angelo
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invitae-joins-nih-sponsored-study-aimed-at-improving-understanding-of-the-links-between-genes-and-cancer-heart-disease-and-other-conditions-301264664.html
SOURCE Invitae Corporation